Monte Rosa Therapeutics (GLUE) Net Equity Issued and Repurchased (2020 - 2025)

Monte Rosa Therapeutics' Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $24.2 million for Q4 2025.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $24.2 million in Q4 2025; TTM through Dec 2025 was $24.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $24.2 million, up 2468.86% from the prior year.
• Net Equity Issued and Repurchased advanced to $24.2 million in Q4 2025 per GLUE's latest filing, from $6.5 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $143.0 million in Q1 2021 and bottomed at -$143.0 million in Q4 2021.
• The 3-year median for Net Equity Issued and Repurchased is $13.5 million (2022), against an average of $8.9 million.
• Biggest YoY gain for Net Equity Issued and Repurchased was 104.58% in 2022; the steepest drop was 104.58% in 2022.
• Year by year, Net Equity Issued and Repurchased stood at -$143.0 million in 2021, then jumped by 104.58% to $6.5 million in 2022, then surged by 270.34% to $24.2 million in 2025.
• Per Business Quant, the three latest GLUE Net Equity Issued and Repurchased figures stand at $24.2 million (Q4 2025), $6.5 million (Q4 2022), and $13.5 million (Q3 2022).